27449818|t|Estradiol prodrugs (EP) for efficient oral estrogen treatment and abolished effects on estrogen modulated liver functions
27449818|a|Oral compared to parenteral estrogen administration is characterized by reduced systemic but prominent hepatic estrogenic effects on lipids, hemostatic factors, GH -/ IGF I axis, angiotensinogen. In order to avoid such adverse metabolic effects of oral treatment, estradiol (E2) prodrugs (EP) were designed which bypass the liver tissue as inactive molecules. Carbone17-OH sulfonamide [-O2-NH2] substituted esters of E2 (EC508, others) were synthesized and tested for carbonic anhydrase II (CA-II) binding. CA II in erythrocytes is thought to oppose extraction of EP from portal vein blood during liver passage. Ovariectomized (OVX, day minus 14) rats were orally treated once daily from day 1-3. Sacrifice day 4. Uteri were dissected and weighed. Cholesterol fractions and angiotensinogen were determined in plasma. Oral E2 and ethinyl estradiol (EE) generated dose related uterine growth and important hepatic estrogenic effects. EP induced uterine growth at about hundred-fold lower doses. This was possible with almost absent effects on plasma cholesterol or angiotensinogen. Preliminary pharmacokinetic studies with EC508 used intravenous and oral administration in male rats. Resulting blood levels revealed complete oral bioavailability. Further high blood - but low plasma concentrations indicated erythrocyte binding of EC508 in vivo as potential mechanism of low extraction at liver passage. Very high systemic estrogenicity combined with markedly lower or absent adverse hepatic estrogenic effects is evidence for a systemic release of E2 from sulfonamide EP. In conclusion, tested oral EP bypass the liver in erythrocytes furnishing systemic estradiol at hydrolysis. This mechanism avoids the hepatic estrogenic impact of conventional oral estrogen therapy.
27449818	0	9	Estradiol	T109,T121,T125	C0014912
27449818	10	18	prodrugs	T120	C0033262
27449818	20	22	EP	T120	C0033262
27449818	38	42	oral	T061	C0001563
27449818	43	61	estrogen treatment	T169	C3173348
27449818	87	95	estrogen	T109,T121,T125	C0014939
27449818	106	121	liver functions	T042	C0232741
27449818	122	126	Oral	T061	C0001563
27449818	139	149	parenteral	T061	C0259961
27449818	150	173	estrogen administration	T169	C3173348
27449818	202	210	systemic	T169	C0205373
27449818	225	232	hepatic	T029	C0205054
27449818	233	251	estrogenic effects	T033	C0877035
27449818	255	261	lipids	T109	C0023779
27449818	263	281	hemostatic factors	T042	C0019116
27449818	283	285	GH	T116,T121,T125	C0037663
27449818	289	294	IGF I	T116,T123	C0021665
27449818	301	316	angiotensinogen	T116,T123	C0003017
27449818	349	366	metabolic effects	T039	C2945675
27449818	370	384	oral treatment	T061	C0001563
27449818	386	395	estradiol	T109,T121,T125	C0014912
27449818	397	399	E2	T109,T121,T125	C0014912
27449818	401	409	prodrugs	T120	C0033262
27449818	411	413	EP	T120	C0033262
27449818	446	458	liver tissue	T023	C0736268
27449818	482	535	Carbone17-OH sulfonamide [-O2-NH2] substituted esters	T104	C1254350
27449818	539	541	E2	T109,T121,T125	C0014912
27449818	543	548	EC508	T109,T121,T125	C0014912
27449818	590	611	carbonic anhydrase II	T116,T126	C0007034
27449818	613	618	CA-II	T116,T126	C0007034
27449818	620	627	binding	T044	C1149286
27449818	629	634	CA II	T116,T126	C0007034
27449818	638	650	erythrocytes	T025	C0014792
27449818	686	688	EP	T120	C0033262
27449818	694	711	portal vein blood	T024	C2324289
27449818	719	724	liver	T023	C0023884
27449818	725	732	passage	T082	C0439799
27449818	734	748	Ovariectomized	T033	C3687559
27449818	750	753	OVX	T033	C3687559
27449818	769	773	rats	T015	C0034721
27449818	779	793	orally treated	T061	C0001563
27449818	836	841	Uteri	T023	C0042149
27449818	847	856	dissected	T169	C0205239
27449818	861	868	weighed	T059	C3827964
27449818	870	891	Cholesterol fractions	T059	C0201950
27449818	896	911	angiotensinogen	T059	C0523500
27449818	931	937	plasma	T031	C0032105
27449818	939	946	Oral E2	T200	C0360514
27449818	951	968	ethinyl estradiol	T109,T121,T125	C0015011
27449818	970	972	EE	T109,T121,T125	C0015011
27449818	997	1004	uterine	T023	C0042149
27449818	1005	1011	growth	T040	C0018270
27449818	1026	1033	hepatic	T029	C0205054
27449818	1034	1052	estrogenic effects	T033	C0877035
27449818	1054	1056	EP	T120	C0033262
27449818	1065	1079	uterine growth	T042	C1326619
27449818	1163	1169	plasma	T031	C0032105
27449818	1170	1181	cholesterol	T109,T123	C0008377
27449818	1185	1200	angiotensinogen	T116,T123	C0003017
27449818	1214	1237	pharmacokinetic studies	T062	C0201734
27449818	1243	1248	EC508	T109,T121,T125	C0014912
27449818	1254	1265	intravenous	T082	C0013125
27449818	1270	1289	oral administration	T061	C0001563
27449818	1293	1297	male	T032	C0086582
27449818	1298	1302	rats	T015	C0034721
27449818	1345	1349	oral	T061	C0001563
27449818	1350	1365	bioavailability	T081	C0005508
27449818	1380	1385	blood	T031	C0005767
27449818	1396	1402	plasma	T031	C0032105
27449818	1428	1439	erythrocyte	T025	C0014792
27449818	1440	1447	binding	T052	C1145667
27449818	1451	1456	EC508	T109,T121,T125	C0014912
27449818	1457	1464	in vivo	T082	C1515655
27449818	1509	1514	liver	T023	C0023884
27449818	1515	1522	passage	T082	C0439799
27449818	1534	1542	systemic	T169	C0205373
27449818	1543	1556	estrogenicity	T109,T121,T125	C0014939
27449818	1604	1611	hepatic	T029	C0205054
27449818	1612	1630	estrogenic effects	T033	C0877035
27449818	1649	1657	systemic	T169	C0205373
27449818	1669	1671	E2	T109,T121,T125	C0014912
27449818	1677	1691	sulfonamide EP	T120	C0033262
27449818	1715	1719	oral	T061	C0001563
27449818	1720	1722	EP	T120	C0033262
27449818	1734	1739	liver	T023	C0023884
27449818	1743	1755	erythrocytes	T025	C0014792
27449818	1767	1775	systemic	T169	C0205373
27449818	1776	1785	estradiol	T109,T121,T125	C0014912
27449818	1789	1799	hydrolysis	T070	C0020291
27449818	1827	1834	hepatic	T029	C0205054
27449818	1835	1845	estrogenic	UnknownType	C0720298
27449818	1869	1873	oral	T061	C0001563
27449818	1874	1890	estrogen therapy	T061	C0279494